Ranbaxy Unveils Anti-Cholesterol Drug

Ranbaxy Laboratories today launched a cholesterol-reducing agent, Rosuvas (rosuvastatin).

Rosuvas is the most aggressive therapy till date for lowering of LDL cholesterol, while also reducing triglycerides and raising HDL, a company release said. The product has been introduced in India by Ranbaxy CV, the cardiovascular division of Ranbaxy.

Rosuvas will compete in the Rs 150 crore statin market, which is growing 23 per cent annually.

Currently, this market has four molecules: atorvastatin, simvastatin, pravastatin and lovastatin.

Ranbaxy has garnered a 20 per cent market share in this segment with its lead brands of Storvas (atorvastatin), Simvotin (simvastatin), Pravator (pravastatin) and Rovacor (lovastatin). The introduction of Rosuvas will further augment Ranbaxy